Ipilimumab-related hypophysitis may precede severe CNS immune attack
Reintroduction of ipilimumab after recovery or hormonal substitution for hypophysitis should be carefully done especially in the presence of minor neurological symptoms or signs (such as tinnitus) which should be considered as red flags for subsequent severe central nervous immune attack.
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-10, Vol.27 (10), p.1975-1976 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1976 |
|---|---|
| container_issue | 10 |
| container_start_page | 1975 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Köessler, T. Olivier, T. Fertani, S. Marinari, E. Dutoit, V. Dietrich, P.-Y. |
| description | Reintroduction of ipilimumab after recovery or hormonal substitution for hypophysitis should be carefully done especially in the presence of minor neurological symptoms or signs (such as tinnitus) which should be considered as red flags for subsequent severe central nervous immune attack. |
| doi_str_mv | 10.1093/annonc/mdw255 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419358934</els_id><sourcerecordid>S0923753419358934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-105802c72e5f8dec4b40cc2a2760af244167f51f08a0c8e7df383a1f1530e2183</originalsourceid><addsrcrecordid>eNp1kL1OwzAURi0EoqUwsqK8QOi1HcfOiMpfpQoGYI4c51o11Elkp0V5e4ICbEx3Ofp0zyHkksI1hYIvddO0jVn6-pMJcUTmVORFqiCjx2QOBeOpFDybkbMY3wEgL1hxSmZMcqG4yufkdt25nfN7r6s04E73WCfboWu77RBd72Li9ZB0AQ3WmEQ8YMBk9fSSOO_3DSa677X5OCcnVu8iXvzcBXm7v3tdPaab54f16maTGp7JPqUgFDAjGQqrajRZlYExTDOZg7Ysy2guraAWlAajUNaWK66ppYIDMqr4gqTTrgltjAFt2QXndRhKCuV3jXKqUU41Rv5q4rt95bH-o3_1R0BOAI5fHxyGMhqHzSjrRuW-rFv3z_QXubpxLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ipilimumab-related hypophysitis may precede severe CNS immune attack</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Köessler, T. ; Olivier, T. ; Fertani, S. ; Marinari, E. ; Dutoit, V. ; Dietrich, P.-Y.</creator><creatorcontrib>Köessler, T. ; Olivier, T. ; Fertani, S. ; Marinari, E. ; Dutoit, V. ; Dietrich, P.-Y.</creatorcontrib><description>Reintroduction of ipilimumab after recovery or hormonal substitution for hypophysitis should be carefully done especially in the presence of minor neurological symptoms or signs (such as tinnitus) which should be considered as red flags for subsequent severe central nervous immune attack.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdw255</identifier><identifier>PMID: 27358386</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Agents, Immunological - adverse effects ; Female ; Humans ; Hypophysitis - chemically induced ; Hypophysitis - diagnosis ; Hypophysitis - immunology ; Ipilimumab - adverse effects ; Middle Aged ; Severity of Illness Index</subject><ispartof>Annals of oncology, 2016-10, Vol.27 (10), p.1975-1976</ispartof><rights>2016 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-105802c72e5f8dec4b40cc2a2760af244167f51f08a0c8e7df383a1f1530e2183</citedby><cites>FETCH-LOGICAL-c347t-105802c72e5f8dec4b40cc2a2760af244167f51f08a0c8e7df383a1f1530e2183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27358386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Köessler, T.</creatorcontrib><creatorcontrib>Olivier, T.</creatorcontrib><creatorcontrib>Fertani, S.</creatorcontrib><creatorcontrib>Marinari, E.</creatorcontrib><creatorcontrib>Dutoit, V.</creatorcontrib><creatorcontrib>Dietrich, P.-Y.</creatorcontrib><title>Ipilimumab-related hypophysitis may precede severe CNS immune attack</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Reintroduction of ipilimumab after recovery or hormonal substitution for hypophysitis should be carefully done especially in the presence of minor neurological symptoms or signs (such as tinnitus) which should be considered as red flags for subsequent severe central nervous immune attack.</description><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypophysitis - chemically induced</subject><subject>Hypophysitis - diagnosis</subject><subject>Hypophysitis - immunology</subject><subject>Ipilimumab - adverse effects</subject><subject>Middle Aged</subject><subject>Severity of Illness Index</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kL1OwzAURi0EoqUwsqK8QOi1HcfOiMpfpQoGYI4c51o11Elkp0V5e4ICbEx3Ofp0zyHkksI1hYIvddO0jVn6-pMJcUTmVORFqiCjx2QOBeOpFDybkbMY3wEgL1hxSmZMcqG4yufkdt25nfN7r6s04E73WCfboWu77RBd72Li9ZB0AQ3WmEQ8YMBk9fSSOO_3DSa677X5OCcnVu8iXvzcBXm7v3tdPaab54f16maTGp7JPqUgFDAjGQqrajRZlYExTDOZg7Ysy2guraAWlAajUNaWK66ppYIDMqr4gqTTrgltjAFt2QXndRhKCuV3jXKqUU41Rv5q4rt95bH-o3_1R0BOAI5fHxyGMhqHzSjrRuW-rFv3z_QXubpxLQ</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Köessler, T.</creator><creator>Olivier, T.</creator><creator>Fertani, S.</creator><creator>Marinari, E.</creator><creator>Dutoit, V.</creator><creator>Dietrich, P.-Y.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201610</creationdate><title>Ipilimumab-related hypophysitis may precede severe CNS immune attack</title><author>Köessler, T. ; Olivier, T. ; Fertani, S. ; Marinari, E. ; Dutoit, V. ; Dietrich, P.-Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-105802c72e5f8dec4b40cc2a2760af244167f51f08a0c8e7df383a1f1530e2183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypophysitis - chemically induced</topic><topic>Hypophysitis - diagnosis</topic><topic>Hypophysitis - immunology</topic><topic>Ipilimumab - adverse effects</topic><topic>Middle Aged</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Köessler, T.</creatorcontrib><creatorcontrib>Olivier, T.</creatorcontrib><creatorcontrib>Fertani, S.</creatorcontrib><creatorcontrib>Marinari, E.</creatorcontrib><creatorcontrib>Dutoit, V.</creatorcontrib><creatorcontrib>Dietrich, P.-Y.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Köessler, T.</au><au>Olivier, T.</au><au>Fertani, S.</au><au>Marinari, E.</au><au>Dutoit, V.</au><au>Dietrich, P.-Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ipilimumab-related hypophysitis may precede severe CNS immune attack</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2016-10</date><risdate>2016</risdate><volume>27</volume><issue>10</issue><spage>1975</spage><epage>1976</epage><pages>1975-1976</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Reintroduction of ipilimumab after recovery or hormonal substitution for hypophysitis should be carefully done especially in the presence of minor neurological symptoms or signs (such as tinnitus) which should be considered as red flags for subsequent severe central nervous immune attack.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27358386</pmid><doi>10.1093/annonc/mdw255</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-10, Vol.27 (10), p.1975-1976 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw255 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents, Immunological - adverse effects Female Humans Hypophysitis - chemically induced Hypophysitis - diagnosis Hypophysitis - immunology Ipilimumab - adverse effects Middle Aged Severity of Illness Index |
| title | Ipilimumab-related hypophysitis may precede severe CNS immune attack |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A36%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ipilimumab-related%20hypophysitis%20may%20precede%20severe%20CNS%20immune%20attack&rft.jtitle=Annals%20of%20oncology&rft.au=K%C3%B6essler,%20T.&rft.date=2016-10&rft.volume=27&rft.issue=10&rft.spage=1975&rft.epage=1976&rft.pages=1975-1976&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdw255&rft_dat=%3Celsevier_cross%3ES0923753419358934%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27358386&rft_els_id=S0923753419358934&rfr_iscdi=true |